Pipeline

Le Life Sciences stanno migliorando radicalmente le possibilità di cura, anche per malattie fino a poco tempo fa prive di una risposta terapeutica. Le nuove conoscenze combinate con la potenza di calcolo sempre crescente e il progresso dell'intelligenza artificiale potranno presto dare risposta ai bisogni insoddisfatti dei pazienti ancor più rapidamente.

Pipeline di sviluppo

Con la nostra pipeline di ricerca e sviluppo, ci rivolgiamo ad alcune delle aree terapeutiche a più alto bisogno di cura.

Platform - Asset	Indication	Phase 1 Phase 2 Phase 3 Post-Market
Ophtha - NGF	Front-of-the-eye: Neurotrophic Keratitis
Ophtha - NGF	Front-of-the-eye: Sjogren-related Dry Eye
Ophtha - NGF Intravitreal	Back-of-the-eye
NETosis - Reparixin	Community Acquired Pneumonia (CAP)
NETosis - Reparixin	Acute Respiratory Distress Syndrome (ARDS)
NETosis - Ladarixin	Type 1 Diabetes – Early Onset
NETosis - Ladarixin	Type 1 Diabetes – Insulin resistant
Primary Care - KLS-Gaba	Low-back pain

Ophtha - NGF

Indication: Front-of-the-eye: Neurotrophic Keratitis

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

Ophtha - NGF

Indication: Front-of-the-eye: Sjogren-related Dry Eye

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

Ophtha - NGF Intravitreal

Indication: Back-of-the-eye

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

NETosis - Reparixin

Indication: Community Acquired Pneumonia (CAP)

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

NETosis - Reparixin

Indication: Acute Respiratory Distress Syndrome (ARDS)

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

NETosis - Ladarixin

Indication: Type 1 Diabetes – Early Onset

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

NETosis - Ladarixin

Indication: Type 1 Diabetes – Insulin resistant

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

Primary Care - KLS-Gaba

Indication: Low-back pain

Project Status:

Phase 1:
Phase 2:
Phase 3:
Post-Market:

Ultime pubblicazioni

Preclinical Programs

Sars-Cov-2

Pain & Antiflammation

Preclinicals Program

Oncology

Preclinicals Programs

Infiammazione E Dolore

Drug repurposing screen to identify inhibitors of the RNA polymerase (nsp12) and helicase (nsp13) from SARS-CoV-2 replication and transcription complex

16/03/2024

Autori: Maria Kuzikov, Jeanette Reinshagen, Krzysztof Wycisk, Angela Corona, Francesca Esposito, Paolo Malune, Candida Manelfi, Daniela Iaconis, Andrea Beccari, Enzo Tramontano, Marcin Nowotny, Björn Windshügel, Philip Gribbon, Andrea Zaliani

Pubblicato in:

Virus Research

Sars-Cov-2

Scopri di più

ProNGF processing in adult rat tissues and bioactivity of NGF prodomain peptides

01/03/2024

Autori: Marie Anne Makoudjou, Elena Fico, Pamela Rosso, Viviana Triaca, Lucio De Simone, Daniela Rossetti, Franca Cattani, Marcello Allegretti and Paola Tirassa

Pubblicato in:

FEBS Open Bio

Preclinical Programs

Scopri di più

"DompeKeys": a set of novel substructure-based descriptros for efficient chemical space mapping, development and structural interpretation of machine learning models, and indexing of large databases

23/02/2024

Autori: Candida Manelfi, Valerio Tazzari, Filippo Lunghini, Carmen Cerchia, Anna Fava, Alessandro Pedretti, Pieter F. W. Stouten, Giulio Vistoli & Andrea Rosario Beccari

Pubblicato in:

Journal of Cheminformatics

Preclinical Programs

Scopri di più

Marcello Allegretti,

Chief Scientific Officer